LANNETT CO INC (LCI)
US5160122009 - Common Stock
Taking everything into account, LCI scores 1 out of 10 in our fundamental rating. LCI was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of LCI have multiple concerns. LCI has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year LCI has reported negative net income.
In the past year LCI has reported a negative cash flow from operations.
LCI had negative earnings in 4 of the past 5 years.
Of the past 5 years LCI 4 years had a positive operating cash flow.
1.2 Ratios
LCI has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of LCI (12.26%) is comparable to the rest of the industry.
LCI's Gross Margin has declined in the last couple of years.
LCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 12.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-36.01%
GM growth 5Y-27.28%
2. Health
2.1 Basic Checks
LCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LCI has been increased compared to 1 year ago.
LCI has less shares outstanding than it did 5 years ago.
The debt/assets ratio for LCI is higher compared to a year ago.
2.2 Solvency
LCI has an Altman-Z score of -1.51. This is a bad value and indicates that LCI is not financially healthy and even has some risk of bankruptcy.
LCI has a Altman-Z score of -1.51. This is comparable to the rest of the industry: LCI outperforms 45.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.51 |
ROIC/WACCN/A
WACC4.16%
2.3 Liquidity
A Current Ratio of 2.23 indicates that LCI has no problem at all paying its short term obligations.
LCI has a worse Current ratio (2.23) than 63.01% of its industry peers.
LCI has a Quick Ratio of 1.39. This is a normal value and indicates that LCI is financially healthy and should not expect problems in meeting its short term obligations.
LCI's Quick ratio of 1.39 is on the low side compared to the rest of the industry. LCI is outperformed by 68.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.23 | ||
| Quick Ratio | 1.39 |
3. Growth
3.1 Past
The earnings per share for LCI have decreased strongly by -129.18% in the last year.
Looking at the last year, LCI shows a very negative growth in Revenue. The Revenue has decreased by -24.09% in the last year.
Measured over the past years, LCI shows a very negative growth in Revenue. The Revenue has been decreasing by -11.78% on average per year.
EPS 1Y (TTM)-129.18%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q12.82%
Revenue 1Y (TTM)-24.09%
Revenue growth 3Y-19.6%
Revenue growth 5Y-11.78%
Revenue growth Q2Q-6.49%
3.2 Future
Based on estimates for the next years, LCI will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.51% on average per year.
Based on estimates for the next years, LCI will show a decrease in Revenue. The Revenue will decrease by -0.68% on average per year.
EPS Next Y-3.01%
EPS Next 2Y4.42%
EPS Next 3Y8.51%
EPS Next 5YN/A
Revenue Next Year-11.78%
Revenue Next 2Y-5.15%
Revenue Next 3Y-0.68%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LCI. In the last year negative earnings were reported.
Also next year LCI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.42%
EPS Next 3Y8.51%
5. Dividend
5.1 Amount
No dividends for LCI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LANNETT CO INC
NYSE:LCI (4/19/2023, 7:06:04 PM)
0.6855
+0.03 (+3.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.38M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 12.26% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.23 | ||
| Quick Ratio | 1.39 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-129.18%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-3.01%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-24.09%
Revenue growth 3Y-19.6%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y